In the present study, experimental AAN was studied in mice as previously described (Baudoux et al. 2012), but Trp53(+/+), Trp53(+/−) and Trp53(−/−) mice were treated with a daily i.p. dose of 3.5 mg/kg bw AAI, instead of 5 mg/kg bw, in order to minimise necrotic lesions in kidneys (Nortier et al., unpublished observation). This evidence concerns the gene TP53 and Balkan nephropathy.